[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC)].
Zittoun
R
R
Service d'Hématologie, Hôtel Dieu, Paris, France.
Rio
B
B
Delmer
A
A
Vekhof
A
A
Mandelli
F
F
Willemze
R
R
de Witte
T
T
Tura
S
S
Ferrini
P R
PR
Stryckmans
P
P
D000206:Actuarial Analysis; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D012074:Remission Induction; D016019:Survival Analysis; D014182:Transplantation, Autologous
D000677:Amsacrine; D003561:Cytarabine; D003630:Daunorubicin
Comparaison des consolidations intensives par autogreffe de moelle ou par chimiothérapie des leucémies aigues myéloblastiques en première rémission complète: protocole AML8A du Leukemia Cooperative Group de l'Organisation Européenne de Recherche et Traitements du Cancer (EORTC).